447 related articles for article (PubMed ID: 22805104)
1. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
Plotkin SR; Merker VL; Halpin C; Jennings D; McKenna MJ; Harris GJ; Barker FG
Otol Neurotol; 2012 Aug; 33(6):1046-52. PubMed ID: 22805104
[TBL] [Abstract][Full Text] [Related]
2. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
Plotkin SR; Stemmer-Rachamimov AO; Barker FG; Halpin C; Padera TP; Tyrrell A; Sorensen AG; Jain RK; di Tomaso E
N Engl J Med; 2009 Jul; 361(4):358-67. PubMed ID: 19587327
[TBL] [Abstract][Full Text] [Related]
3. Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium.
Fisher LM; Doherty JK; Lev MH; Slattery WH
Otol Neurotol; 2009 Sep; 30(6):835-41. PubMed ID: 19704365
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.
Hochart A; Gaillard V; Baroncini M; André N; Vannier JP; Vinchon M; Dubrulle F; Lejeune JP; Vincent C; Nève V; Sudour Bonnange H; Bonne NX; Leblond P
J Neurooncol; 2015 Sep; 124(2):229-36. PubMed ID: 26022982
[TBL] [Abstract][Full Text] [Related]
5. Surgical management of vestibular schwannomas and hearing rehabilitation in neurofibromatosis type 2.
Tysome JR; Macfarlane R; Durie-Gair J; Donnelly N; Mannion R; Knight R; Harris F; Vanat ZH; Tam YC; Burton K; Hensiek A; Raymond FL; Moffat DA; Axon PR
Otol Neurotol; 2012 Apr; 33(3):466-72. PubMed ID: 22334163
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy.
Eminowicz GK; Raman R; Conibear J; Plowman PN
J Laryngol Otol; 2012 Jan; 126(1):79-82. PubMed ID: 22004800
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
Plotkin SR; Halpin C; McKenna MJ; Loeffler JS; Batchelor TT; Barker FG
Otol Neurotol; 2010 Sep; 31(7):1135-43. PubMed ID: 20736812
[TBL] [Abstract][Full Text] [Related]
8. Linear accelerator-based stereotactic radiosurgery for bilateral vestibular schwannomas in patients with neurofibromatosis type 2.
Meijer OW; Vandertop WP; Lagerwaard FJ; Slotman BJ
Neurosurgery; 2008 May; 62(5 Suppl):A37-42; discussion A42-3. PubMed ID: 18580779
[TBL] [Abstract][Full Text] [Related]
9. Cochlear implantation in patients with neurofibromatosis type 2 and bilateral vestibular schwannoma.
Lustig LR; Yeagle J; Driscoll CL; Blevins N; Francis H; Niparko JK
Otol Neurotol; 2006 Jun; 27(4):512-8. PubMed ID: 16791043
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
Blakeley JO; Ye X; Duda DG; Halpin CF; Bergner AL; Muzikansky A; Merker VL; Gerstner ER; Fayad LM; Ahlawat S; Jacobs MA; Jain RK; Zalewski C; Dombi E; Widemann BC; Plotkin SR
J Clin Oncol; 2016 May; 34(14):1669-75. PubMed ID: 26976425
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab for Hearing Preservation in Neurofibromatosis Type 2: Emphasis on Patient-Reported Outcomes and Toxicities.
Sverak P; Adams ME; Haines SJ; Levine SC; Nascene D; Sommer K; Dusenbery K; Huang TC; Moertel C
Otolaryngol Head Neck Surg; 2019 Mar; 160(3):526-532. PubMed ID: 30373466
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.
Nunes FP; Merker VL; Jennings D; Caruso PA; di Tomaso E; Muzikansky A; Barker FG; Stemmer-Rachamimov A; Plotkin SR
PLoS One; 2013; 8(3):e59941. PubMed ID: 23555840
[TBL] [Abstract][Full Text] [Related]
13. Hearing improvement after bevacizumab for neurofibromatosis type 2.
Diao JS; Xia WS; Guo SZ
N Engl J Med; 2009 Oct; 361(18):1810; author reply 1810-1. PubMed ID: 19877310
[No Abstract] [Full Text] [Related]
14. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
Plotkin SR; Duda DG; Muzikansky A; Allen J; Blakeley J; Rosser T; Campian JL; Clapp DW; Fisher MJ; Tonsgard J; Ullrich N; Thomas C; Cutter G; Korf B; Packer R; Karajannis MA
J Clin Oncol; 2019 Dec; 37(35):3446-3454. PubMed ID: 31626572
[TBL] [Abstract][Full Text] [Related]
15. The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.
Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3627-33. PubMed ID: 25421643
[TBL] [Abstract][Full Text] [Related]
16. Middle fossa decompression for hearing preservation: a review of institutional results and indications.
Slattery WH; Hoa M; Bonne N; Friedman RA; Schwartz MS; Fisher LM; Brackmann DE
Otol Neurotol; 2011 Aug; 32(6):1017-24. PubMed ID: 21725256
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.
Mautner VF; Nguyen R; Kutta H; Fuensterer C; Bokemeyer C; Hagel C; Friedrich RE; Panse J
Neuro Oncol; 2010 Jan; 12(1):14-8. PubMed ID: 20150363
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab treatment for vestibular schwannoma in a patient with neurofibromatosis type 2: hearing improvement and tumor shrinkage.
Sponghini AP; Platini F; Rondonotti D; Soffietti R
Tumori; 2015 Nov; 101(6):e167-70. PubMed ID: 26108240
[TBL] [Abstract][Full Text] [Related]
19. Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2.
Farschtschi S; Kollmann P; Dalchow C; Stein A; Mautner VF
Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3857-60. PubMed ID: 25794543
[TBL] [Abstract][Full Text] [Related]
20. Clinical course of vestibular schwannoma in pediatric neurofibromatosis Type 2.
Choi JW; Lee JY; Phi JH; Wang KC; Chung HT; Paek SH; Kim DG; Park SH; Kim SK
J Neurosurg Pediatr; 2014 Jun; 13(6):650-7. PubMed ID: 24724714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
